Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/?FIREFLY-2)
Complete Title: Day101-002; LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial Of DAY101 Monotherapy Versus Standard Of Care Chemotherapy In Patients With Pediatric Low-Grade Glioma Harboring An Activating RAF Alteration Requiring First-Line Systemic Therapy
Trial Phase: III
Investigator: Erin Crotty
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
Keywords:
- Glioma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.